aidsmeds
Gene Therapy Controls HIV Longer Than Four Months in Study
Sangamo Biosciences’ efforts to develop genetic therapies for HIV have had some early success, with two of three participants in one cohort maintaining control of the virus for an extended period during which they were not taking standard antiretroviral (ARV) treatment. The biotech company is conducting a Phase I/II study, known as SB-728-1101, of its…
.png)